文献速递乳腺癌支持与姑息治疗

接受化疗的育龄乳腺癌女性抗苗勒管激素水平及其变化

Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
PubMed 文献 · Eur J Cancer · 2017-01-28

本综述通过系统检索PubMed(截至2016年4月)相关文献,描述育龄乳腺癌女性化疗前、化疗期间及化疗后血清抗苗勒管激素(AMH)水平的变化,并探讨紫杉类对AMH的影响、AMH与闭经的关联及AMH与其他卵巢储备激素标志物的比较。

要点

  • 化疗期间多数患者AMH迅速降至检测不到水平,治疗后多持续处于很低水平
  • AMH可预测化疗相关闭经,是卵巢储备最相关的激素标志物
  • 紫杉类似乎对卵巢功能有负面影响,但卵巢储备数据稀少

核心结论

  • 血清AMH是绝经前乳腺癌女性卵巢储备评估和治疗期间随访的相关工具。
  • 需进一步大型前瞻性研究以确定AMH对治疗后残余生育力的预测价值,并最终用于治疗开始前的生育力保存咨询。

研究设计与样本

  • 系统综述:对截至2016年4月发表的所有相关文章进行系统PubMed检索。
  • 检索关键词包括AMH、苗勒管抑制物质、卵巢储备、卵巢功能、乳腺癌、性腺毒性、卵巢毒性、闭经、化疗和绝经。

主要发现

  • 化疗期间多数女性AMH水平迅速降至检测不到的水平。
  • 治疗后多数女性AMH一般持续处于很低水平。
  • 紫杉类似乎对卵巢功能有负面影响,但有关卵巢储备的数据稀少。
  • AMH是化疗相关闭经发生的预测因素,并且是卵巢储备最相关的激素标志物。

临床怎么用

  • 血清AMH可用于绝经前乳腺癌女性卵巢储备评估及治疗期间随访。
  • 作者认为,需进一步大型前瞻性研究确定AMH对治疗后残余生育力的预测价值。
  • 作者认为,AMH最终可用于治疗开始前的生育力保存咨询。

局限性

  • 紫杉类对卵巢储备影响的数据稀少。
  • 需进一步大型前瞻性研究以确定AMH对治疗后残余生育力的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term consequences of cancer treatments in young women, and especially fertility issues, are gaining attention as survival rates increase. Breast cancer is the most frequent malignancy in women of reproductive age. AIM: The purpose of this review is to describe serum anti-müllerian hormone (AMH) level at diagnosis and its evolution during and after chemotherapy in women of reproductive age treated for breast cancer. Second, the impact of taxanes on AMH, the association between AMH and amenorrhea, and the comparison of AMH with other hormonal markers of ovarian reserve were studied. METHODS: A systematic PubMed search was conducted on all articles, published up to April 2016 and related to AMH in women suffering from breast cancer using the following key words: AMH, müllerian-inhibiting substance, ovarian reserve, ovarian function, breast cancer, gonadotoxicity, ovarian toxicity, amenorrhea, chemotherapy, and menopause. RESULTS: AMH levels rapidly fall down to undetectable levels in most women during chemotherapy and generally persist at very low levels in most women after the treatment. Taxanes seem to impact negatively ovarian function, but data on ovarian reserve are scarce. AMH is a predictor of the occurrence of chemotherapy-related amenorrhea and is the most relevant hormonal marker of ovarian reserve. CONCLUSION: Serum AMH is a relevant tool for ovarian reserve assessment and follow-up during treatment in premenopausal women with breast cancer. Further large prospective studies are necessary to determine its predictive interest for post-treatment residual fertility, and eventually use it in fertility preservation counseling before treatment initiation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fréour T, Barrière P, Masson D, et al. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017. PMID: 28135602. doi:10.1016/j.ejca.2016.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。